菜单
Service Overviews

Background: Considering current problems of antibody preparation technology, such as extended preparation cycle, heavy screening workload, and limited number of candidate antibodies, especially difficulty for challenging targets, Sanyou Bio has built a "Sanyou Bio Super- trillion Innovative Antibody Discovery Platform" characterized by technology integration with comprehensive fundamental solution to the screening of innovative antibody candidate molecules.


Methods: In this platform, animal immunity, fully human or immune source-derived recombinant B-cell antibodies, construction of synthetic and semi-synthetic antibody library, phage display antibody library, mammalian cell expression of recombinant antibody, automation and high-throughput screening were integrated.


Advantages: Integrate nine super-trillion antibody libraries with a super-large capacity of ten-trillion-level library; Thousands of lead molecules in primary screening is guaranteed, complemented by the 2nd screening with eukaryotic protein; full coverage of such molecular forms as single domain, monoclonal antibody, polyclonal antibody, polypeptide, and small protein with multi-approach generation through immuno-derived, natural, recombinant, synthetic, and semi-synthetic pathways; adaptable to cross-screening of various antigens, capable of handling any highly challenging targets; one-stop panning combined with precise screening proven by nearly one hundred projects.


Compositions: This platform was developed with 7 years of continuous efforts in innovation and R&D and completely owned by Sanyou Bio. The platform consisting of nine core super-trillion antibody libraries has a capacity of up to 10 trillion, including "a series of trillion antibody libraries" and "immunological recombinant monoclonal antibodies". Up to now, the trillion fully human recombinant antibody library, trillion fully human semi-synthetic antibody library, trillion humanized 2C/4C single domain antibody library, trillion fully human common light chain monoclonal antibody library, magnetic & immunization & tandem mouse antibody library, and magnetic & immunization & tandem alpaca antibody library have been constructed.


This platform was developed with 7 years of continuous efforts in innovation and R&D and completely owned by Sanyou Bio. The platform consisting of nine core super-trillion antibody libraries has a capacity of up to 10 trillion, including "a series of trillion antibody libraries" and "immunological recombinant monoclonal antibodies". Up to now, the trillion fully human antibody library, trillion fully human semi-synthetic antibody library, trillion fully human 2C/4C single domain antibody library, trillion fully human common light chain monoclonal antibody library, magnetic & immunization & tandem mouse antibody library, and magnetic & immunization & tandem alpaca antibody library have been constructed.


Service Overview Background: Considering current problems of antibody preparation technology, such as extended preparation cycle, heavy screening workload, and limited number of candidate antibodies, especially difficulty for challenging targets, Sanyou Bio has built a "Sanyou Bio Super- trillion Innovative Antibody Discovery Platform" characterized by technology integration with comprehensive fundamental solution to the screening of innovative antibody candidate molecules. Methods: In this platform, animal immunity, fully human or immune source-derived recombinant B-cell antibodies, construction of synthetic and semi-synthetic antibody library, phage display antibody library, mammalian cell expression of recombinant antibody, automation and high-throughput screening were integrated. Advantages: Integrate nine super-trillion antibody libraries with a super-large capacity of ten-trillion-level library; Thousands of lead molecules in primary screening is guaranteed, complemented by the 2nd screening with eukaryotic protein; full coverage of such molecular forms as single domain, monoclonal antibody, polyclonal antibody, polypeptide, and small protein with multi-approach generation through immuno-derived, natural, recombinant, synthetic, and semi-synthetic pathways; adaptable to cross-screening of various antigens, capable of handling any highly challenging targets; one-stop panning combined with precise screening proven by nearly one hundred projects. Composition: This platform was developed with 7 years of continuous efforts in innovation and R&D and completely owned by Sanyou Bio. The platform consisting of nine core super-trillion antibody libraries has a capacity of up to 10 trillion, including "a series of trillion antibody libraries" and "immunological recombinant monoclonal antibodies". Up to now, the trillion fully human recombinant antibody library, trillion fully human semi-synthetic antibody library, trillion fully human 2C/4C single domain antibody library, trillion fully human common light chain monoclonal antibody library, magnetic & immunization & tandem mouse antibody library, and magnetic & immunization & tandem alpaca antibody library have been constructed. This platform was developed with 7 years of continuous efforts in innovation and R&D and completely owned by Sanyou Bio. The platform consisting of nine core super-trillion antibody libraries has a capacity of up to 10 trillion, including "a series of trillion antibody libraries" and "immunological recombinant monoclonal antibodies". Up to now, the trillion fully human recombinant antibody library, trillion fully human semi-synthetic antibody library, trillion fully human 2C/4C single domain antibody library, trillion fully human common light chain monoclonal antibody library, magnetic & immunization & tandem mouse antibody library, and magnetic & immunization & tandem alpaca antibody library have been constructed. Service Highlights The trillion library matrix integrates antibody generation technologies such as "fully human natural B cells, alpaca/mouse immune B cells, single domain antibodies, recombinant antibodies, synthetic antibodies, and semi- synthetic antibodies", which meet the needs of all types of molecules, including "fully human antibodies, humanized single domain antibodies, humanized mouse monoclonal antibodies, bispecific monoclonal antibodies, polyclonal antibodies, polypeptides, ADC, PDC, and miniaturized proteins", and is capable of obtaining candidate molecules at high speed and high success rate which are close to nature with high affinity, high druggability and high developability. 1. Trillion Fully Human Recombinant Antibody Library Trillion library capacity. Recombinant antibody library of fully human B cells after cloning. Coming from nature with good developability. Lead molecule median: 300+. 2. Trillion Fully Human Semi-synthetic Antibody Library Trillion library capacity. Antibody library of fully human B cells after rearrangement. Coming from nature with engineering design and great diversity. Lead molecule median: 300+. 3. Trillion Fully Human 2C-type Single Domain Antibody Library 2-trillion library capacity. Humanization degree of antibody framework reaches 98%. 2C-type single domain synthetic antibody library. Lead molecule median: 600+. 4. Trillion Fully Human 4C-type Single Domain Antibody Library 2-trillion library capacity. Humanization degree of antibody framework reaches 98%. 4C-type single domain synthetic antibody library that is more stable and more degradation-resistant. Lead molecule median: 600+. 5. Trillion Fully Human Common Light Chain Monoclonal Antibody Library Trillion library capacity. Recombinant antibody library with a combination of selected light chains and diversified heavy chains. Coming from fully human natural antibodies, with selected light chains and diversified heavy chains. Lead molecule median: 300+. 6. Trillion Cyclic Polypeptide Library Trillion library capacity A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides. Suitable for the drug R&D of PDC, oral, and intracellular target. Lead molecule median (estimated): 100+. 7. Magnetic & Immunization & Tandem Mouse Antibody Library Large library capacity and clear sequences saving several months compared with hybridoma. Diversified antigens, mouse, immune pathway, and cross screening. Recombinant antibody library of mouse B cells cloning after immunization. Lead molecule median: 40+. 8. Magnetic & Immunization & Tandem Alpaca Antibody Library Large library capacity and clear sequences. Diversified antigens, immune pathway, and cross screening. Single domain antibody obtained directly. Lead molecule median: 30+. Platform Center Pillar: One-Stop Automatic and High-Throughput Screening In 2022, the Sanyou Bio one-stop automatic and high-throughput screening workstation officially started to serve the antibody screening using trillion libraries, covering four key nodes: high-throughput panning, high-throughput screening, high-throughput construction, and high-throughput expression. The seamless connection between "phage display antibody library and mammalian cell protein expression" can help realize automatic, high-throughput, and precise screening. Compared with traditional methods, this platform can accelerate the R&D process by substantially improving the speed of screening and construction. Service Features 1. Coming from Nature, Supplemented by Engineering 1.1. Coming from nature The amino acid ratios of the sites of the light chain and heavy chain CDR3 regions of the antibodies from the Sanyou Bio trillion fully human recombinant antibody library are shown in Figure 1, which indicates the extremely high abundance of antibody sequences in the Sanyou Bio trillion fully human recombinant antibody library, and its consistency with amnio acid ratios in the native antibody library. Fig. 1A CDR-L3 AA frequency Fig. 1B CDR-H3 AA frequency 1.2. Fully Human Framework The antibodies in the Sanyou Bio super-trillion antibody library are all designed with fully human framework, which ensures that the antibodies screened are more similar to the natural ones to facilitate the antibody engineering. 1.3. High Diversity The evolutionary tree drawn according to the antibodies screened from the Sanyou Bio super-trillion antibody library is shown in the right figure, which indicates the extremely high abundance of antibody sequences in the Sanyou Bio trillion fully human recombinant antibody library, and high diversity of the sequence. 2. Adaptability to Various Targets and Molecule Forms 2.1. Perfect Solutions to Most Challenging Targets and Other Targets The number of lead antibodies obtained for targets of varied difficulties has been collected. For most challenging targets (multi-transmembrane proteins), regular targets (single-transmembrane proteins), and easy targets (cytokines), an average of 295, 268, and 366 lead molecules can be obtained from the trillion fully human recombinant/semi-synthetic libraries and an average of 581, 790, and 580 lead molecules can be obtained from the trillion fully human single domain antibody library, respectively. This proves our capability to obtain from the trillion library a considerable number of lead antibodies for the more difficult targets like multi- transmembrane or cytokines, which can serve as a perfect solution to the antibody drug screening of different types of targets including the most challenging targets. Fig. 2 Number of lead antibodies obtained for targets with different difficulties 2.2. Hundreds and Thousands of Lead Molecules Obtained for Any Target The number of lead antibodies from varied antibody libraries has been collected. Using Sanyou Bio trillion fully human recombinant/semi-synthetic library, the screening of 16 targets produces the lead molecule at a median of 345 and an average of 317; Using Sanyou Bio trillion fully human single domain antibody library, the screening of 14 targets produces the lead molecule at a median of 606 and an average of 673. Fig. 3 Statistics of lead antibodies from varied antibody libraries 2.3. High Antibody Affinity The affinity kinetic statistics of the 608 candidate antibodies from 9 projects showed that the affinity of 86 candidate molecules (14%) was above 10-10 M, and that of 372 ones (61%) was above 10-9 M. In general, the statistics were distributed normally. Fig. 4 Antibody affinity statistics Case Presentations 1. Milestone Projects 2. Cases from Each Library 3. Representative Cases 3.1. IND Phase Projects FDA clinical approval for monoclonal antibody A project CDE clinical approval for monoclonal antibody B project CDE pre-IND approval for bispecific monoclonal antibody C project FDA pre-IND approval for bispecific monoclonal antibody C project Multiple project papers published in top journals 3.2. Representative Cases 3.2.1. P/H/V Tri-specific Antibody Drug Fig. 5 Molecule diagram Fig. 6 In vitro drug efficacy Fig. 7 . In vivo neutralizing activity 3.2.2. C/D Bi-specific Antibody Drug Fig. 8 Molecule diagram Fig. 9 In vitro drug efficacy Fig. 10 In vivo neutralizing activity

Service Highlights

The trillion library matrix integrates antibody generation technologies such as "fully human natural B cells, alpaca/mouse immune B cells, single domain antibodies, recombinant antibodies, synthetic antibodies, and semi- synthetic antibodies", which meet the needs of all types of molecules, including "fully human antibodies, humanized single domain antibodies, humanized mouse monoclonal antibodies, bispecific monoclonal antibodies, polyclonal antibodies, polypeptides, ADC, PDC, and miniaturized proteins", and is capable of obtaining candidate molecules at high speed and high success rate which are close to nature with high affinity, high druggability and high developability.


  • 1. Trillion fully human recombinant antibody library
    1. Trillion library capacity.
    2. Recombinant antibody library of fully human B cells after cloning.
    3. Coming from nature with good developability.
    4. Lead molecule median: 300+.
  • 2. Trillion fully human semi-synthetic antibody library
    1. Trillion library capacity.
    2. Antibody library of fully human B cells after rearrangement.
    3. Coming from nature with engineering design and great diversity.
    4. Lead molecule median: 300+.
  • 3. Trillion fully human 2C-type single domain antibody library
    1. 2-trillion library capacity.
    2. Humanization degree of antibody framework reaches 98%.
    3. 2C-type single domain synthetic antibody library.
    4. Lead molecule median: 600+.
  • 4. Trillion fully human 4C-type single domain antibody library
    1. 2-trillion library capacity.
    2. Humanization degree of antibody framework reaches 98%.
    3. 4C-type single domain synthetic antibody library that is more stable and more degradation-resistant.
    4. Lead molecule median: 600+.
  • 5. Trillion fully human common light chain monoclonal antibody library
    1. Trillion library capacity.
    2. Recombinant antibody library with a combination of selected light chains and diversified heavy chains.
    3. Coming from fully human natural antibodies, with selected light chains and diversified heavy chains.
    4. Lead molecule median: 300+.
  • 6. Trillion cyclic polypeptide library
    1. Trillion library capacity.
    2. A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides.
    3. Suitable for the drug R&D of PDC, oral, and intracellular target.
    4. Lead molecule median (estimated): 100+.
  • 7. Magnetic & Immunization & Tandem mouse antibody library
    1. Large library capacity and clear sequences saving several months compared with hybridoma.
    2. Diversified antigens, mouse, immune pathway, and cross screening.
    3. Recombinant antibody library of mouse B cells cloning after immunization.
    4. Lead molecule median: 40+.
  • 8. Magnetic & Immunization & Tandem alpaca antibody library
    1. Large library capacity and clear sequences.
    2. Diversified antigens, immune pathway, and cross screening.
    3. Single domain antibody obtained directly.
    4. Lead molecule median: 30+.
Platform center pillar: One-stop automatic and high-throughput screening


In 2022, the Sanyou Bio one-stop automatic and high-throughput screening workstation officially started to serve the antibody screening using trillion libraries, covering four key nodes: high-throughput panning, high-throughput screening, high-throughput construction, and high-throughput expression. The seamless connection between "phage display antibody library and mammalian cell protein expression" can help realize automatic, high-throughput, and precise screening. Compared with traditional methods, this platform can accelerate the R&D process by substantially improving the speed of screening and construction.



Service Features
1. Coming from nature, supplemented by engineering

1.1. Coming from nature

The amino acid ratios of the sites of the light chain and heavy chain CDR3 regions of the antibodies from the Sanyou Bio trillion fully human recombinant antibody library are shown in Figure 1, which indicates the extremely high abundance of antibody sequences in the Sanyou Bio trillion fully human recombinant antibody library, and its consistency with amnio acid ratios in the native antibody library.


Fig. 1A CDR-L3 AA frequency


Fig. 1B CDR-H3 AA frequency


1.2. Fully human framework

The antibodies in the Sanyou Bio super-trillion antibody library are all designed with fully human framework, which ensures that the antibodies screened are more similar to the natural ones to facilitate the antibody engineering.



1.3. High diversity

The evolutionary tree drawn according to the antibodies screened from the Sanyou Bio super-trillion antibody library is shown in the right figure, which indicates the extremely high abundance of antibody sequences in the Sanyou Bio trillion fully human recombinant antibody library, and high diversity of the sequence.


2. Adaptability to various targets and molecule forms

2.1. Perfect solutions to most challenging targets and other targets

The number of lead antibodies obtained for targets of varied difficulties has been collected. For most challenging targets (multi-transmembrane proteins), regular targets (single-transmembrane proteins), and easy targets (cytokines), an average of 295, 268, and 366 lead molecules can be obtained from the trillion fully human recombinant/semi-synthetic libraries and an average of 581, 790, and 580 lead molecules can be obtained from the trillion fully human single domain antibody library, respectively. This proves our capability to obtain from the trillion library a considerable number of lead antibodies for the more difficult targets like multi- transmembrane or cytokines, which can serve as a perfect solution to the antibody drug screening of different types of targets including the most challenging targets.


Fig. 2 Number of lead antibodies obtained for targets with different difficulties


2.2. Hundreds and thousands of lead molecules obtained for any target

The number of lead antibodies from varied antibody libraries has been collected. Using Sanyou Bio trillion fully human semi-synthetic library, the screening of 16 targets produces the lead molecule at a median of 345 and an average of 317; Using Sanyou Bio trillion fully human single domain antibody library, the screening of 14 targets produces the lead molecule at a median of 606 and an average of 673.


Fig. 3 Statistics of lead antibodies from varied antibody libraries


2.3. High antibody affinity

The affinity kinetic statistics of the 608 candidate antibodies from 9 projects showed that the affinity of 86 candidate molecules (14%) was above 10-10 M, and that of 372 ones (61%) was above 10-9 M. In general, the statistics were distributed normally.


Fig. 4 Antibody affinity statistics


Case Studies
1. Milestone projects
2. Cases from each library
3. Representative cases

3.1. IND phase projects


FDA clinical approval for monoclonal antibody A project


CDE clinical approval for monoclonal antibody B project


CDE pre-IND approval for bispecific monoclonal antibody C project


FDA pre-IND approval for bispecific monoclonal antibody C project



Multiple project papers published in top journals


3.2. Representative cases

3.2.1. P/H/V tri-specific antibody drug


Fig. 5 Molecule diagram


Fig. 6 In vitro drug efficacy


Fig. 7 . In vivo neutralizing activity


3.2.2. C/D bi-specific antibody drug


Fig. 8 Molecule diagram


Fig. 9 In vitro drug efficacy


Fig. 10 In vivo neutralizing activity